Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PDE4A | P27815 | 6/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1061386 | 0.92 | ALDH1A1 (0.51) | ALDH1A1LMNAPDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL1565880 | 0.90 | ALDH1A1 (0.50) | ALDH1A1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL3399025 | 0.88 | ADORA2A (0.42) | ALDH1A1LMNAPDE4APDE4BPDE4C | |
| Hydrochloric Acid SCHEMBL28143496 | 0.86 | ALDH1A1 (0.43) | ALDH1A1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL5687930 | 0.84 | PDE4A (0.47) | ALDH1A1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL1546765 | 0.82 | PDE4A (0.46) | ALDH1A1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL4251917 | 0.81 | PDE4A (0.46) | ALDH1A1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL28429328 | 0.80 | TSHR (0.46) | ALDH1A1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL1546080 | 0.79 | SIRT1 (0.46) | ALDH1A1LMNAPDE4APDE4BPDE4C | |
| SCHEMBL242052 | 0.79 | ALDH1A1 (0.41) | ALDH1A1LMNAPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8609671-B2 | Method of inhibiting hepatic fibrosis as a result of liver replacement or repair using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-8466129-B2 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466129-B2 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466129-B2 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2012-08-30 | — | — | US | disclosed |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2012-08-30 | — | — | US | disclosed |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. | 2012-08-30 | — | — | US | disclosed |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD SCIENCES, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD SCIENCES, INC. | 2007-09-20 | — | — | US | disclosed |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | GILEAD SCIENCES, INC. | 2007-09-20 | — | — | US | disclosed |
| EP-1789053-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060281921-A1 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-7125993-B2 | A2B adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20060159627-A1 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006028810-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. | 2006-03-16 | — | — | US | disclosed |
| US-20040176399-A1 | A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243358-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 156/4885LMNA 1544/4885PDE4A 259/4885 |
| US-20070219221-A1 | administration of therapeutically effective amount of 3-ethyl-1-propyl-8-(1-{[3-(trifluoromethyl)phenyl]methyl}pyrazol-4-yl)-1,3,7-trihydropurine-2,6-dione, wherein hepatic disease is selected from necrosis, fibrosis, cholestasis, cirrhosis, viral and alcoholic hepatitis, ingestion of hepatotoxic drugs | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 150/4885LMNA 2648/4885PDE4A 325/4885 |
| US-20060281921-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 870/4885LMNA 3818/4885PDE4A 41/4885 |
| US-20120220608-A1 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 156/4885LMNA 1544/4885PDE4A 259/4885 |
| US-20040176399-A1 | A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 779/4885LMNA 3889/4885PDE4A 27/4885 |
| US-20060058322-A1 | Method of wound healing using A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ALDH1A1 470/4885LMNA 2855/4885PDE4A 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.